CVS Health Co. (NYSE:CVS) Stake Boosted by Ossiam

Ossiam raised its position in shares of CVS Health Co. (NYSE:CVS) by 45.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 33,586 shares of the pharmacy operator’s stock after buying an additional 10,553 shares during the quarter. Ossiam’s holdings in CVS Health were worth $1,508,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. BI Asset Management Fondsmaeglerselskab A S boosted its stake in CVS Health by 3.8% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 473,067 shares of the pharmacy operator’s stock worth $21,236,000 after purchasing an additional 17,428 shares during the period. Beck Mack & Oliver LLC boosted its position in shares of CVS Health by 1.1% in the fourth quarter. Beck Mack & Oliver LLC now owns 20,425 shares of the pharmacy operator’s stock worth $917,000 after buying an additional 232 shares during the period. Capital International Inc. CA grew its holdings in shares of CVS Health by 49.2% during the fourth quarter. Capital International Inc. CA now owns 415,408 shares of the pharmacy operator’s stock valued at $18,648,000 after buying an additional 136,976 shares in the last quarter. Capital World Investors raised its position in CVS Health by 26.6% during the fourth quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator’s stock valued at $2,739,927,000 after buying an additional 12,819,148 shares during the period. Finally, Claret Asset Management Corp lifted its stake in CVS Health by 10.4% in the 4th quarter. Claret Asset Management Corp now owns 301,743 shares of the pharmacy operator’s stock worth $13,545,000 after acquiring an additional 28,500 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Price Performance

NYSE CVS opened at $67.19 on Monday. The stock has a market capitalization of $84.71 billion, a PE ratio of 18.36, a P/E/G ratio of 0.98 and a beta of 0.57. The stock has a 50-day simple moving average of $66.46 and a 200 day simple moving average of $58.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $71.45.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Research analysts anticipate that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be paid a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.96%. The ex-dividend date is Tuesday, April 22nd. CVS Health’s payout ratio is presently 72.68%.

Insider Buying and Selling

In other news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael F. Mahoney bought 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the purchase, the director now directly owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. 1.22% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on CVS. Mizuho lifted their target price on CVS Health from $70.00 to $76.00 and gave the company an “outperform” rating in a research note on Wednesday, April 9th. Edward Jones upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a research report on Thursday, January 30th. Evercore ISI boosted their price target on shares of CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Monday, January 27th. Barclays increased their price objective on CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Finally, StockNews.com raised CVS Health from a “sell” rating to a “hold” rating in a research report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $71.83.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.